'Why rifampicin works for staphylococcal biofilm infection'

Dr. Michael Otto

Chief, Pathogen Molecular Genetics Section,
National Institute of Allergy and Infectious Diseases (NIAID), USA



Date: July 2 (Tue) 2024

Time: 3 pm – 4 pm

Venue: Taniguchi Memorial Hall, RIMD

Chair: Yumi Matsuoka (Cutaneous Allergy and Host Defense)

Dr Otto
https://www.niaid.nih.gov/research/michael-otto-phd

*A credit seminar for the Graduate School of Medicine and the Graduate School of Frontier Biosciences

Dr. Michael Otto earned his Ph.D. in microbiology. He joined the Laboratory of Human Bacterial Pathogenesis in July 2001 as a principal investigator. In 2008, he became a tenured senior investigator and moved his laboratory to the NIH Bethesda main campus.

His Laboratory (Pathogen Molecular Genetics section) investigates physiology and host interaction of Gram-positive pathogens with a focus on Staphylococcus aureus and coagulase-negative staphylococci. We are also investigating the interactions of commensal staphylococci with other bacteria within the human microbiome and the potential of probiotic approaches to control bacterial infections.